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Abstract
Background : The association between daily alcohol intake and changes in renal function in the 
Japanese general population is not well established.
Methods : We analyzed data from 150 residents who underwent specific health checkups held in 
Mishima Town in 2016 and 2019. We divided participants on the basis of alcohol consumption :  
residents with daily alcohol intake of < 20 g/day (the none-to-low group, n = 104, 69.3%) ; those 
with daily alcohol intake of ≥ 20 but < 40 g/day (the intermediate group, n = 30, 20.0%) ; and those 
with daily alcohol intake of ≥ 40 g/day (the high group, n = 16, 10.7%). We compared baseline 
characteristics. The primary endpoint was a decrease in estimated glomerular filtration rate 
(eGFR), defined as the decrease in eGFR greater than the median decrease over three years.
Results : The three-year changes in eGFR were +0.3 (−4.8, +3.0), −2.3 (−5.1, +1.2), and −4.9 
(−8.2, −2.9) mL/min/1.73 m2 in the none-to-low, intermediate, and high groups, respectively (P = 
0.007). In the multivariate logistic regression analysis, a high amount of alcohol intake was inde-
pendently associated with a decrease in eGFR, with adjusted odds ratio of 11.418 (95% confidence 
interval 1.554-83.879, P = 0.017).
Conclusion : A high average daily alcohol intake is associated with a decrease in eGFR.
Key words : glomerular filtration rate, renal function, specific health checkup, general population, 
alcohol
Introduction
Renal function is a strong predictor of high mor-
tality not only in patients with heart failure1), but 
also in the general population2). All-cause and car-
diovascular mortality increase with a reduction of 
estimated glomerular filtration rate (eGFR) below 
75 mL/min/1.73 m2 in the general population2).　
However, baseline renal function is unmodifiable, 
and it is crucial to predict and prevent deterioration 
in renal function3).
Specific health checkups are useful to detect 
residents who are at a high risk of cardiovascular 
disease, and are a good opportunity to provide life-
style interventions4). However, the usefulness of 
specific health checkups for predicting deterioration 
in renal function has not been fully examined, espe-
cially in the general population with normal renal 
function. Regarding modifiability, alcohol consump-
tion is a target for lifestyle intervention5-8). How-
ever, the association between daily alcohol intake 
and change in renal function has not been fully ex-
amined, particularly among Japanese. Thus, to 
clarify these issues in a general population with nor-
mal renal function, we carried out a cross-sequential 
and longitudinal observational study of specific 
health checkup results in collaboration with local 
government authorities involved in the administra-
tion of Japan’s universal healthcare system.
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Methods
Subjects and protocol
This was a cross-sequential and longitudinal 
observational study of specific health checkups held 
in Mishima Town in Onuma County, Fukushima Pre-
fecture, Japan. Residents aged 40-74 years old 
were eligible for the checkups. A study flowchart 
is shown in the Figure. We collected all the results 
of National Health Insurance beneficiaries who un-
derwent specific health checkups both in 2016 and 
2019 (n = 187). Residents who lacked data on 
eGFR (n = 3) and those with eGFR of < 60 mL/
min/1.73 m2 in 2016 (n = 34) were excluded. Fi-
nally, a total of 150 residents (70 male, 46.7% ; me-
dian age 67.0 years old) were included in the study.　
We divided participants on the basis of alcohol con-
sumption :  residents with daily alcohol intake of 
< 20 g/day (the none-to-low group, n = 104, 
69.3%) ;  those with daily alcohol intake of ≥ 20 but 
< 40 g/day (the intermediate group, n = 30, 20.0%) ; 
and those with daily alcohol intake of ≥ 40 g/day (the 
high group, n = 16, 10.7%). This study complied 
with the Declaration of Helsinki and the statement 
of STROBE (Strengthening the Reporting of Obser-
vational studies in Epidemiology)9,10). In addition, 
since the participants’ information was anonymized 
and de-identified at the Mishima Town Office prior 
to analysis, written informed consent was not re-
quired or obtained from each resident, but opt-out 
methods were explained in public reports of the cur-
rent study11). The study was publicized by posting 
a summary of the protocol on the website of Fuku-
shima Prefectural Miyashita Hospital, at Mishima 
Town Office, and in Mishima Town’s public relations 
magazine, where a notice clearly informed all resi-
dents of their right to refuse enrollment. The 
study protocol was approved by the research ethics 
committee of Fukushima Prefectural Miyashita Hos-
pital (No. 20190001) and registered under the Japa-
nese UMIN Clinical Trials Registration (UMIN 
000036620).
We compared baseline (2016) demographic data, 
social history, past medical history, and the results of 
blood and urine tests among the three groups. In-
formation about social history and past medical his-
tory was obtained from a standardized questionnaire.　
Regarding alcohol intake, participants were asked 
“How much do you drink per day, when converted to 
volume of sake?” with four response options (1, < 180 
mL ; 2, ≥ 180 but < 360 mL ; 3, ≥ 360 but < 540 
mL ; 4, ≥ 540 mL) and a conversion table “180 mL 
of sake is equivalent to 500 mL of beer, 110 mL of 
shochu, 60 mL of whiskey (a double), and 240 mL of 
wine.” In the present study, 180 mL of sake was 
defined as containing 20 g of alcohol. Blood and 
urine tests were performed in a fasting state. The 
modified Modification of Diet in Renal Disease equa-
tion was used to calculate eGFR : eGFR (mL/min/ 
1.73 m2) = 194 * serum creatinine (−1.094) * age (−0.287) 
* 0.739 (if female)12). The rate of annual eGFR de-
cline in the general Japanese population has been re-
ported to be 0.36 mL/min/1.73 m2, but this rate is af-
fected by the coexisting diseases and baseline eGFR13).　
In this study, we set the primary outcome as a de-
crease in eGFR greater than the median decrease in 
this study population. The median three-year 
change in eGFR of the whole study population was 
−1.4 mL/min/1.73 m2. Thus, change in eGFR over 
three years below −1.4 mL/min/1.73 m2 was defined 
as a decrease in eGFR.
Statistical analysis
Continuous variables were presented as median 
(25th percentile, 75th percentile) and categorical 
variables were expressed as counts and percentages.　
The Jonckheere-Terpstra trend test and the Co-
chran-Armitage trend test were used for the com-
parisons of continuous and categorical variables, re-
spectively. To avoid the problem of multiple 
comparisons, P values of the pairwise comparisons 
of groups after the Jonckheere-Terpstra trend test 
were adjusted by the Bonferroni correction. The 
impact of alcohol intake on a decrease in eGFR was 
assessed using logistic regression analysis. Odds 
ratios were then adjusted for age and sex, and fur-
ther adjusted for established factors associated with 
deterioration in eGFR, namely age, sex, body mass 
index, current smoking, hypertension, diabetes mel-
litus, dyslipidemia, estimated glomerular filtration 
rate, and urine albumin-to-creatinine ratio13-15). P 
values of < 0.05 were considered statistically signifi-
cant for all analyses. The Cochran-Armitage trend 
test was performed using EZR (Saitama Medical 
Center, Jichi Medical University, Saitama, Japan) 
which is a graphical user interface for R (The R 
Foundation for Statistical Computing, Vienna, Aus-
tria)16) and all other analyses were performed using 
SPSS ver. 26 (IBM, Armonk, NY, USA).
Results
In the current study, 16 of the 150 residents 
(10.7%) belonged to the high group (Figure). Base-
line characteristics are shown in Table 1. The 
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three-year changes in eGFR were +0.3 (−4.8, 
+3.0), −2.3 (−5.1, +1.2), and −4.9 (−8.2, −2.9) 
mL/min/1.73 m2 in the none-to-low, intermediate, 
and high groups, respectively (P = 0.007). There 
was no trend in age among groups, but the percent-
age of males increased with alcohol consumption 
(none-to-low, 67.0 years, 30.8% male ; intermediate 
68.0 years, 73.3% male ; high, 63.5 years, 100.0% 
male, P < 0.001). Regarding social history and past 
medical history, there were significant trends in cur-
rent smoking, diabetes mellitus, and hyperuricemia.　
Blood tests revealed that there was no trend in lev-
els of baseline eGFR among the groups (P = 0.728) 
while there were significant trends from the none-
to-low group to the high group in levels of liver en-
zymes. As to urine tests, there was no statistical 
trend in urine albumin-to-creatinine ratio.
The results of logistic regression analysis are 
summarized in Table 2. In the unadjusted model, a 
high amount of alcohol intake was associated with a 
decrease in eGFR compared to a low none-to-low 
amount as reference (odds ratio 9.545, 95% confi-
dence interval 2.063-44.163, P = 0.004). After ad-
justment for pre-specified confounding factors, a 
high amount of alcohol intake was independently as-
sociated with a decrease in eGFR with adjusted odds 
ratio of 11.418 (95% confidence interval 1.554-
83.879, P = 0.017).
Discussion
In this cross-sequential and longitudinal obser-
vational study, we found that a high amount of alco-
hol intake was significantly associated with a de-
crease in eGFR. The strength of this study was 
that we obtained data from specific health checkups 
available through a system of universal healthcare, 
so our results can be extrapolated to the general 
population with normal renal function. This study 
is of importance not only for daily clinical practice, 
but also for public policy, because we found that po-
tential deterioration in eGFR can be estimated by 
specific health checkups.
The association between alcohol intake and 
prognosis remains controversial. Historically, a 
small amount of alcohol intake was considered to 
contribute to the reduction of all-cause mortality in 
the general population17,18). However, this J-curve 
phenomenon disappears after adjustment for bias 
and study characteristics19). A recent systematic 
analysis revealed that zero alcohol intake minimizes 
the overall risk to health20). Alcohol intake increas-
es the risk of chronic diseases including cancer, de-
pression, alcohol use disorders, hypertension, and 
cirrhosis5,21-23). On the other hand, the impact of al-
cohol consumption on renal function is still contro-
versial. A large cohort study of female nurses re-
ported that the amount of alcohol intake was not 
associated with later renal dysfunction24), while a 
retrospective case-control study reported an associ-
ation between alcohol consumption and end-stage 
renal disease25). According to a recent meta-analy-
sis, alcohol consumption was inversely associated 
with risk for developing CKD26). However, there 
have been some studies that showed competing re-
sults27,28). A large community-based observational 
study in Japan, in which intermediate and high 
amounts of alcohol consumption were not distin-
guished, reported that an alcohol intake of more than 
20 g/day had a neutral impact on later development 
of CKD29). The present study also focused on a 
Japanese general population, namely, participants 
with normal renal function who were eligible for 
specific health checkups. Our results suggest that 
a high amount of alcohol consumption (40 g/day or 
more) is associated with a decrease in eGFR. The 
Figure. Study subject flowchart
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discrepancy of the impact of alcohol consumption on 
renal function remains controversial. Drinking 
habits are influenced by cultural and genetic back-
grounds over the world30,31). Although polyphenols 
show anti-atherosclerotic effects, amounts of poly-
phenols differs according to the types of beverages 
(wine, beer, etc.)32). As to genetic background, an 
allele of rs671 in aldehyde dehydrogenase 2 (ALDH2), 
a functional variant involved in alcohol metabolism, 
is specifically prevalent among East Asian popula-
tions33,34). A meta-analysis of genome-wide associ-
ation studies for kidney function-related traits rev-
eled that some loci including ALDH2 are associated 
with kidney function35). Thus, the impact of alcohol 
intake should be further elucidated, taking account 
of the type of beverages and characteristics of the 
study population. In addition, according to a large-
scale Mendelian randomization analysis, an allele of 
rs1229984 in alcohol dehydrogenase 1B (ADH1B), a 
genetic variant associated with none or minimal al-
cohol intake, expresses a cardiovascular-protective 
profile36).








Change in eGFR 
(mL/min/1.73 m2)
+0.3 (−4.8, +3.0) −2.3 (−5.1, +1.2) −4.9 (−8.2, -2.9)* 0.007
Decrease in eGFR (n, %) 44 (42.3) 17 (56.7) 14 (87.5) <0.001
Demographic data
Age (years) 67.0 (64.0, 70.0) 68.0 (65.0, 69.0) 63.5 (59.5, 66.5) 0.104
Male (n, %) 32 (30.8) 22 (73.3) 16 (100.0) <0.001
Body mass index (kg/m2) 23.1 (21.2, 24.8) 24.1 (22.2, 25.3) 25.2 (21.6, 26.5) 0.041
Systolic BP (mmHg) 124.0 (114.0, 136.0) 129.0 (118.0, 136.0) 128.0 (120.5, 136.0) 0.279
Diastolic BP (mmHg) 73.0 (67.0, 80.0) 77.5 (71.0, 82.0) 74.5 (69.0, 84.0) 0.105
Social history
Smoking history (pack-years) 0.0 (0.0, 15.0) 3.3 (0.0, 30.0) 35.5 (0.5, 43.0)* <0.001
Current smoking (n, %) 9 (8.7) 5 (16.7) 8 (50.0) <0.001
Past medical history
Hypertension (n, %) 40 (38.5) 10 (33.3) 11 (68.8) 0.095
Diabetes mellitus (n, %) 14 (13.5) 1 (3.3) 0 (0.0) 0.036
Dyslipidemia (n, %) 51 (49.0) 7 (23.3) 9 (56.3) 0.512
Cerebrovascular accident (n, %) 3 (2.9) 3 (10.0) 0 (0.0) 0.748
Heart disease (n, %) 6 (5.8) 1 (3.3) 0 (0.0) 0.278
Hyperuricemia (n, %) 4 (3.8) 3 (10.0) 3 (18.8) 0.018
Blood test
eGFR (mL/min/1.73 m2) 72.4 (65.7, 77.5) 68.9 (63.5, 75.8) 73.1 (69.3, 82.1) 0.728
Hemoglobin (g/dL) 13.6 (12.9, 14.8) 15.1 (14.0, 15.5)* 14.9 (14.4, 15.2)* <0.001
FBG (mg/dL) 98.5 (93.0, 107.0) 102.0 (94.0, 109.5) 101.0 (95.0, 104.5) 0.225
HbA1c (%) 5.7 (5.4, 5.9) 5.6 (5.3, 5.8) 5.6 (5.4, 5.9) 0.196
HDL cholesterol (mg/dL) 60.0 (50.0, 73.5) 63.0 (50.0, 72.0) 57.0 (49.5, 66.5) 0.599
LDL cholesterol (mg/dL) 116.5 (104.0, 138.0) 124.0 (102.0, 142.0) 119.5 (101.5, 130.5) 0.986
Triglycerides (mg/dL) 86.0 (61.5, 116.5) 86.5 (75.0, 122.0) 111.5 (81.5, 291.0)* 0.008
Total cholesterol (mg/dL) 198.0 (175.5, 217.5) 205.0 (174.0, 230.0) 195.5 (177.5, 222.5) 0.570
AST (U/L) 22.0 (19.0, 25.0) 23.0 (21.0, 26.0) 26.0 (23.5, 33.0)*† 0.001
ALT (U/L) 16.0 (13.0, 20.5) 17.5 (15.0, 21.0) 24.5 (20.0, 28.0)*† 0.001
GGT (U/L) 20.0 (15.0, 30.0) 33.0 (20.0, 54.0)* 42.5 (32.0, 83.5)* <0.001
Uric acid (mg/dL) 4.8 (4.1, 5.8) 6.1 (5.1, 6.5)* 6.2 (5.9, 7.3)* <0.001
Urine test
UACR (mg/g) 5.3 (3.9, 8.8) 5.5 (3.7, 7.2) 7.0 (4.1, 16.4) 0.695
eGFR, estimated glomerular filtration rate ; BP, blood pressure ; FBG, fasting blood glucose ; HbA1c, hemoglobin 
A1c ;  HDL, high density lipoprotein ; LDL, low density lipoprotein ; AST, aspartate transaminase ; ALT, alanine 
transaminase ;  GGT, γ-glutamyltransferase ; UACR, urine albumin-to-creatinine ratio.
*adjusted P < 0.05 vs. none-to-low and † adjusted P < 0.05 vs. intermediate after the Bonferroni correction.
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Since the current study was based on specific 
health checkups performed in a single town, the 
number of participants was relatively small. Thus, 
our results should be considered preliminary, and 
further studies or meta-analyses are necessary to 
confirm our findings. The amount of alcohol intake 
in 2016 was self-reported and changes in alcohol in-
take over the three years were not considered. In 
addition, taking into account the situations in which 
one typically drinks alcohol, the salt and protein 
from snacks consumed while drinking may have had 
an effect on the participants’ renal function. How-
ever, these data were not available in the database 
used for our study.
In conclusion, a high amount of alcohol intake is 
associated with a decrease in eGFR in a Japanese 
cohort with normal renal function.
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